Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$24.2 million.

  • Heron Therapeutics' Free Cash Flow fell 54.73% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.1 million, marking a year-over-year decrease of 246.99%. This contributed to the annual value of -$24.2 million for FY2024, which is 59.83% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Free Cash Flow is -$24.2 million, which was up 59.83% from -$60.3 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Free Cash Flow ranged from a high of -$24.2 million in FY2024 and a low of -$206.4 million during FY2021.
  • Over the past 3 years, Heron Therapeutics' median Free Cash Flow value was -$60.3 million (recorded in 2023), while the average stood at -$77.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 45.47% in 2020, then spiked by 59.83% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Free Cash Flow stood at -$191.6 million in 2020, then decreased by 7.69% to -$206.4 million in 2021, then grew by 27.93% to -$148.7 million in 2022, then skyrocketed by 59.44% to -$60.3 million in 2023, then surged by 59.83% to -$24.2 million in 2024.